

TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED

(Company Registration No.: 91120000103100784F)

(Incorporated in the People's Republic of China)

Resolutions Passed at the 4th Board Meeting for FY2018

The board of directors (the "Board") of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited collectively and individually accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the "**Company**") has, on 9 August 2018, convened the 4th board meeting. The following resolutions were discussed and passed by the 7 directors out of the full board of 7 directors.

The said meeting was convened in compliance with the applicable Companies Law, Securities Law and the Articles of Association of the Company, and the following resolutions were passed:

1. That, the proposed change in the use of the net proceeds raised from the placement be approved;
2. That, the proposed change in the amount of the net proceeds raised from the placement be approved;
3. That, the loan facilities to a limit of RMB200,000,000 granted to the Company be approved;

The Company has received bank facilities from the following banks:

No.	Name of the bank	Line of Credit (RMB)	Maturity Term
1	Agricultural Development Bank of China	200,000,000	One year

4. That, the proposed removal of the "purchase and sale through agents, and wholesale and retail of cigarettes business" as one of the current businesses of the Company be approved; and
5. That, the proposed convening of the second Extraordinary General Meeting in 2018 be approved.

The above resolution from No.1 to No.4 shall be tabled for shareholders' approval, at the second Extraordinary General Meeting to be convened in due course.

By order of the Board

9 August 2018